[CAS NO. 114870-03-0] Fondaparinux sodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [114870-03-0]

Catalog

HY-B0597

Brand

MCE

CAS

114870-03-0

DESCRIPTION [114870-03-0]

Overview

MDL	MFCD06794972
Molecular Weight	1728.08
Molecular Formula	C31H43N3Na10O49S8
SMILES	O[C@H]([C@@H](O)[C@@H]1O[C@](O[C@H](COS(=O)(O[Na])=O)[C@@H](O)[C@@H]2O)([H])[C@@H]2NS(=O)(O[Na])=O)[C@](O[C@@H]1C(O[Na])=O)([H])O[C@H]([C@H](O[C@@H]3O[C@]([C@@H]4O)([H])[C@@H](O[C@@H](O[C@]([C@@H]5O)([H])[C@H](O[C@H](OC)[C@@H]5NS(=O)(O[Na])=O)COS(=O)(O[Na])=O)[C@@H]4OS(=O)(O[Na])=O)C(O[Na])=O)COS(=O)(O[Na])=O)[C@@H]([C@H]3NS(=O)(O[Na])=O)OS(=O)(O[Na])=O

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

IC50 & Target

Factor Xa ^[1]

In Vitro

Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC ₅₀ values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs) ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01121770	Duke University\|GlaxoSmithKline	Renal Insufficiency	May 2010	Phase 1
NCT00333021	GlaxoSmithKline	Venous Thromboembolism	May 2006	Phase 3
NCT00060554	Schering-Plough	Myocardial Infarction\|Coronary Disease	April 2003	Phase 2
NCT00038961	GlaxoSmithKline\|Sanofi	Thromboembolism	November 2001	Phase 3
NCT00378027	The Cleveland Clinic\|GlaxoSmithKline	Pulmonary Embolism	August 2006
NCT00767559	The New England Baptist Hospital	Pulmonary Embolism	November 2008	Not Applicable
NCT00474591	Hamilton Health Sciences Corporation\|GlaxoSmithKline\|McMaster University	Coronary Bypass Graft Failure+Occlusion		Phase 3
NCT04359212	Quovadis Associazione\|Azienda Ospedaliera di Padova	COVID-19 Disease\|Thromboembolism, Venous	May 1, 2020
NCT00320398	GlaxoSmithKline	Thrombosis, Venous	January 30, 2006	Phase 3
NCT01444612	GlaxoSmithKline	Thrombosis, Venous	February 2010
NCT00789399	Prairie Education and Research Cooperative\|American College of Phlebology	Deep Vein Thrombosis\|Coronary Artery Bypass Surgery\|Venous Thromboembolism	November 19, 2009	Not Applicable
NCT00981409	GlaxoSmithKline	Embolism, Pulmonary	July 2007	Phase 3
NCT01727401	G. d´Annunzio University	Medical Patient\|Thrombocytopenia	November 2012	Phase 4
NCT01428531	GlaxoSmithKline	Ataxia	January 2012
NCT00464087	Medstar Health Research Institute\|GlaxoSmithKline	Acute Coronary Syndromes	June 2007	Phase 3
NCT00909064	Paul Di Cesare,MD\|University of California, Davis	Total Knee Replacement	June 2009	Phase 4
NCT00377091	University of Minnesota\|GlaxoSmithKline	Pulmonary Embolism	June 2007	Phase 4
NCT00659399	NYU Langone Health\|GlaxoSmithKline	Ovarian Carcinoma	January 2008	Phase 1
NCT00603824	Methodist Healthcare\|University of Tennessee	Heparin-Induced Thrombocytopenia	January 2008	Phase 4
NCT00064428	GlaxoSmithKline\|Sanofi	Thromboembolism	August 2003	Phase 3
NCT01064362	GlaxoSmithKline	Thrombosis, Venous	January 2010
NCT00881088	Red Cross Hospital Beverwijk	Deep Vein Thrombosis\|Pulmonary Embolism	April 2009	Phase 2\|Phase 3
NCT02744092	Alliance Foundation Trials, LLC.\|Patient-Centered Outcomes Research Institute	Cancer\|Venous Thromboembolism\|Deep Vein Thrombosis (DVT)\|Pulmonary Embolism (PE)\|Blood Clot	December 2016	Not Applicable
NCT01390883	GlaxoSmithKline	Cardiovascular Disease	December 2008
NCT00911157	GlaxoSmithKline	Thrombosis, Venous	June 2008	Phase 3
NCT01267305	Shanghai Zhongshan Hospital	Lung Neoplasms\|Esophageal Neoplasms\|Venous Thromboembolism	January 2011	Not Applicable
NCT00320424	GlaxoSmithKline	Thromboembolism	February 16, 2006	Phase 3
NCT01467583	Wayne State University\|GlaxoSmithKline	Venous Thromboembolism	November 2011	Phase 4
NCT00790907	GlaxoSmithKline	Acute Coronary Syndrome	February 2009	Phase 4
NCT01304238	GlaxoSmithKline	Acute HIT II (Heparin-induced Thrombocytopenia Type II)	February 2009
NCT00412464	Children´s Hospital Los Angeles\|FDA Office of Orphan Products Development	Thrombosis\|Heparin-induced Thrombocytopenia	September 2006	Phase 1
NCT01428544	GlaxoSmithKline	Ataxia	March 2012
NCT00443053	GlaxoSmithKline	Thrombosis, Venous	March 2007	Phase 3
NCT00531843	Mary Knudson, M.D.\|GlaxoSmithKline\|University of California, San Francisco	Venous Thromboembolism	December 2007	Phase 2\|Phase 3
NCT00381888	Masonic Cancer Center, University of Minnesota	Cervical Cancer\|Endometrial Cancer\|Fallopian Tube Cancer\|Ovarian Cancer\|Sarcoma\|Thromboembolism\|Vaginal Cancer\|Vulvar Cancer	January 2007	Phase 2
NCT01691495	GlaxoSmithKline	Thrombosis, Venous	October 2012
NCT00256100	Melbourne Health	Renal Failure	June 2004	Not Applicable
NCT04368377	University of Milan\|Fondazione Un Cuore per Milano - a no profit foundation	Pneumonia, Viral\|Corona Virus Infection\|Respiratory Failure\|Embolism and Thrombosis	April 6, 2020	Phase 2
NCT00673439	University of Louisville\|James Graham Brown Cancer Center	Heparin-Induced Thrombocytopenia	November 2007	Phase 2
NCT05001776	National Medical Research Center for Therapy and Preventive Medicine	Superficial Vein Thrombosis\|Endovenous Laser Ablation	August 16, 2021	Phase 4
NCT00346879	Indiana University School of Medicine\|American Society for Bariatric Surgery\|Indiana University	Morbid Obesity	August 2006	Phase 1
NCT00413504	Brigham and Women´s Hospital\|GlaxoSmithKline	Deep Vein Thrombosis\|Pulmonary Embolism	April 2006	Not Applicable
NCT00911300	GlaxoSmithKline	Fibrillation, Atrial	August 2009	Phase 2
NCT01004939	GlaxoSmithKline	Thromboembolism\|Venous Thromboembolism	March 2010
NCT00436787	University of Pittsburgh\|GlaxoSmithKline	Venous Thrombosis\|Pulmonary Embolism	February 2007	Phase 2
NCT00139815	GlaxoSmithKline\|University of Chicago\|Organon\|Sanofi\|Duke University	Thromboembolism	April 2003	Phase 3
NCT01499953	GWT-TUD GmbH\|Bayer	Superficial Vein Thrombosis	April 2012	Phase 3
NCT00894283	Johns Hopkins University\|GlaxoSmithKline	Deep Venous Thrombosis\|Pulmonary Embolism	June 2009	Early Phase 1
NCT04447378	National University of Malaysia	Thromboembolism in the Puerperium	September 1, 2017	Phase 4
NCT01406301	GlaxoSmithKline	Acute Coronary Syndrome	March 2008
NCT00493896	Eastern Virginia Medical School\|GlaxoSmithKline	Venous Thromboembolism	July 2007	Phase 3
NCT01390896	GlaxoSmithKline	Cardiovascular Disease	September 2009
NCT00843492	GlaxoSmithKline	Thrombosis, Venous	December 2008	Phase 3
NCT00483600	Duke University\|GlaxoSmithKline	Kidney Diseases	August 2007	Not Applicable
NCT00424281	Wayne State University\|GlaxoSmithKline	ICU Patients 18 Years or Older.	February 2007
NCT00927602	Università degli Studi dell´Insubria	Medical Patients\|Renal Insufficiency	April 2009	Phase 4
NCT00555438	Centre Hospitalier Universitaire de Saint Etienne\|GlaxoSmithKline	Major Orthopaedic Surgery and Renal Impairment	June 2007	Phase 4
NCT01857583	Daiichi Sankyo Co., Ltd.\|Daiichi Sankyo, Inc.	Venous Thromboembolism	March 2012	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 125 mg/mL ( 72.33 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.5787 mL	2.8934 mL	5.7868 mL
5 mM	0.1157 mL	0.5787 mL	1.1574 mL
10 mM	0.0579 mL	0.2893 mL	0.5787 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (57.87 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-β-D-glucopyranuronosyl-(1→4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1→4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10)

IC 851589

SR 90107A

Fondaparinux sodium

Arixtra

Xantidar

Fondaparin sodium

Org 31540

IC 85158

Fondaparinux

Fondaparin

Quixidar